InVivo Therapeutics Corporation Engages FDA With Second Product, a Novel Drug Releasing Hydrogel for Chronic Pain Treatment

Published: Jul 02, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurological injuries, today announced a novel hydrogel based product for the treatment of acute and sub-acute sciatica or radicular pain of the low back and legs and/or acute and sub-acute radicular pain of the neck or arms.

Back to news